Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024

Ovid Therapeutics Inc.

Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.
Primary completion date now estimated March 2024; regulatory filings expected in Takeda's fiscal 2024.
Takeda stated studies remain highest-priority late-stage programs; actively recruiting with multiple approaches to minimize delays.
Ovid retains significant financial interest in soticlestat's development and potential commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.